12:51 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Depression Analysis of a patient adverse event database and mouse studies suggest promoting the expression of HspH1 could help treat depression. In the FDA Adverse Event Reporting System (FAERS) database, the incidence of depression...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...
02:36 , May 13, 2015 |  BC Extra  |  Company News

Baxter buys Sigma-Tau leukemia portfolio

Baxter International Inc. (NYSE:BAX) acquired a portfolio of leukemia products from Sigma-Tau Group (Pomezia, Italy) for $900 million. The portfolio includes Oncaspar pegasparagase , which is marketed to treat acute lymphoblastic leukemia (ALL), and calaspargase...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Enzon infectious news

Enzon's board adopted a stockholder rights plan to reduce the likelihood of an "unintended" ownership change. Under the plan, shareholders on record on May 14 will be issued one right for each common share held....
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Hologic diagnostic news

Hologic entered into a nomination and standstill deal with activist investor Carl Icahn. The company appointed Jonathan Christodoro and Samuel Merksamer, both managing directors at Icahn Capital L.P., as directors. Christodoro is also a director...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Enzon, Santaris deal

Santaris reacquired from Enzon rights, data, products and IP related to locked nucleic acid (LNA) platform to treat cancer after the companies mutually terminated their 2006 deal. Santaris said the program includes "several" compounds in...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

lncRNA meets the androgen receptor

Although many long noncoding RNAs are upregulated in cancer, relatively few have been shown to functionally contribute to disease. 1 Now, a U.S. team has found that two lncRNAs act directly on the androgen receptor...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Financial News

Enzon financial update

Enzon said it will distribute the company's excess cash from ongoing royalty revenues to shareholders through periodic dividends, including a special dividend of $1.60 per share to be paid on June 4 to shareholders on...
07:00 , Apr 29, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.09 to $3.29 on Friday after EMA's CHMP backed an MAA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). The company markets the product in the U.S. for...